Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement. As such, astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands.
Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by literally regrowing damaged tissue and restoring organ functions through the use of tissue engineering and stem cell therapy. This is the promise of regenerative medicine.
Regenerative Medicine Markets discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures.
The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions.
Additional Information
Press Release
Regenerative Medicine Market to Catapult to Over $35 Billion by 2019
New York, NY, February xx, 2013 – TriMarkPublications.com cites in its newly published “Regenerative Medicine Markets” report that the regenerative medicine market will catapult to over $35 billion by 2019.
Regenerative medicine (RM) can be categorized into three main modalities: tissue engineering, biomaterials and biomolecules, e.g., scaffolds, growth factors and stem cell therapy. Tissue-engineered bone products in the orthopedic segment will see steady growth, from $7.5 billion in 2012 to $3.29 billion in 2019. The up-and-coming cardiology and vascular products segment will also see substantial growth, reaching a market value of $3.29 over the forecast period.
The “Regenerative Medicine Markets” report covers:
- Tissue-engineered skin, cartilage, bone, peripheral nerves, corneas and blood vessels
- Sell culture products
- Stem cell transplants
- Pluripotent, neural, RPE and limbal stem cells
- Cartilage repair
- Skin ulcers
- Facial reconstruction bone
- Tendon, ligament and blood vessel repair
- Myocardial patches
- Heart valve repair
- Kidney repair
- Bladder repair
- Liver repair
- Bioartificial pancreas
The “Regenerative Medicine Markets” report examines companies manufacturing regenerative medicine equipment and supplies in the world. Companies covered include: Amorcyte, Ars Arthro, Axiogenesis, AxoGen, Bellicum, BetaStem, Bioheart, Biomet, BioMimetic, BioTissue, Biovest, BrainStorm Cell, California Stem Cell, Cardio3, Cellartis, CellSeed, Cellular, Chromocell, Cognate, Cook, Cytomedix, Cytonet, Cytori, DanDrit, Fibrocell, Forticell, Gamida, Harvest, Histogenics, Humacyte, Integra, Intercytex, iPierian, Japan Tissue Engineering, Kensey Nash, Kiadis, Life Cell, Living Cell, MaxCyte, MediStem, Mesoblast, MolMed, NanoCor, Neuralstem, NeuroNova, NewLink Genetics, Olympus Terumo, OncoMed, Opexa, Organogenesis, Orthovita, Osiris, Osteotech, Pervasis, Pluristem, Proneuronnologies, RegeneRx, ReNeuron, Revivicor, SanBio, Saneron, Sangamo, Stem Cell Authority, StemCells, Stemline, Stratetech, Synthecon, Tengion, Thermogenesis, TiGenics, Tissue Genesis, ViaCyte, Vistagen and Zen-Bio.
